This trial will test the safety and performance of a new device to treat tricuspid valve disease.
2 Primary · 7 Secondary · Reporting Duration: 30 days, 6 Months, 12 Months
Experimental Treatment
55 Total Participants · 1 Treatment Group
Primary Treatment: Transcatheter Tricuspid Valve Reconstruction · No Placebo Group · N/A
Age 18+ · All Participants · 3 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: